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ABSTRACT
Ewing sarcoma is an undifferentiated small-round-cell sarcoma. Although 
molecular detection of pathognomonic EWSR1-ETS fusions such as EWSR1-FLI1 
enables definitive diagnosis, substantial confusion can arise if molecular diagnostics 
are unavailable. Diagnosis based on the conventional immunohistochemical marker 
CD99 is unreliable due to its abundant expression in morphological mimics.
To identify novel diagnostic immunohistochemical markers for Ewing sarcoma, 
we performed comparative expression analyses in 768 tumors representing 21 
entities including Ewing-like sarcomas, which confirmed that CIC-DUX4-, BCOR-
CCNB3-, EWSR1-NFATc2-, and EWSR1-ETS-translocated sarcomas are distinct entities, 
and revealed that ATP1A1, BCL11B, and GLG1 constitute specific markers for Ewing 
sarcoma. Their high expression was validated by immunohistochemistry and proved 
to depend on EWSR1-FLI1-binding to highly active proximal super-enhancers. 
Automated cut-off-finding and combination-testing in a tissue-microarray comprising 
174 samples demonstrated that detection of high BCL11B and/or GLG1 expression is 
sufficient to reach 96% specificity for Ewing sarcoma. While 88% of tested Ewing-like 
sarcomas displayed strong CD99-immunoreactivity, none displayed combined strong 
BCL11B- and GLG1-immunoreactivity.
Collectively, we show that ATP1A1, BCL11B, and GLG1 are EWSR1-FLI1 targets, 
of which BCL11B and GLG1 offer a fast, simple, and cost-efficient way to diagnose 
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INTRODUCTION
Ewing sarcoma is characterized by the presence of 
chimeric EWSR1-ETS fusion oncogenes [1]. Before the 
discovery of this unifying genetic hallmark, diagnosing 
Ewing sarcoma definitively was challenging [2] as Ewing 
sarcoma tumors are largely composed of undifferentiated 
cells displaying a small-round-cell phenotype [3, 4]. This 
phenotype is shared by many other tumor entities such 
as rhabdomyosarcoma and neuroblastoma [5]. Recently, 
several so-called Ewing-like sarcoma subtypes have been 
identified [6-9]. These tumors are characterized by distinct 
fusion oncogenes and transcriptomic signatures [6-12], as 
well as (most likely) by distinct clinical behavior [6, 12, 
13]. 
Although Ewing sarcoma can usually be reliably 
distinguished from its morphological mimics by 
cytogenetic and molecular genetic analyses [14, 15], 
there is currently no robust biomarker available for 
routine histology. Substantial diagnostic confusion can 
arise because sophisticated cytogenetic and molecular 
diagnostic techniques are not universally available or 
too expensive for some diagnostic facilities (particularly 
in developing countries). While the widely used 
immunohistochemical biomarker CD99 shows high 
sensitivity for Ewing sarcoma, its low specificity and 
high expression in morphological mimics such as CIC- 
and BCOR-rearranged sarcomas, as well as in certain 
lymphoma subtypes and poorly differentiated synovial 
sarcoma, are problematic [3, 11-13, 16-18]. Thus, 
CD99 alone is unreliable to definitively diagnose Ewing 
sarcoma. Other studies identified auxiliary markers such 
as NKX2-2 and FLI1, which may help in some cases [19, 
20]. However, a systematic and agnostic transcriptome-
wide screen for auxiliary markers and testing of their 
value when used in combination has not been done so 
far. In the current study, comparative expression analyses 
revealed that ATP1A1, BCL11B, and GLG1 constitute 
potential specific markers for Ewing sarcoma. Expression 
of these genes appeared to be induced by EWSR1-FLI1-
bound super-enhancers, which showed high activity in 
reporter assays. Specific immunohistochemical staining 
of these proteins in comprehensive tissue microarrays 
(TMAs) combined with automated cut-off determination 
and combination-testing demonstrated that detecting high 
BCL11B and/or GLG1 levels is sufficient to reach 96% 
specificity for Ewing sarcoma. In fact, these markers were 
extremely effective at discriminating Ewing sarcoma from 
Ewing-like sarcomas.
Hence, these results provide a fast, simple, and 
cost-efficient means of diagnosing Ewing sarcoma by 
immunohistochemistry (IHC), which is a considerable 
advantage for diagnostic facilities where molecular 
diagnostics are not available. This finding may 
significantly reduce the number of misdiagnosed patients 
and thus improve patient care.
RESULTS
ATP1A1, BCL11B, and GLG1 are strongly 
overexpressed in Ewing sarcoma compared to 
tumor entities of differential diagnostic relevance
To identify highly specific diagnostic markers 
for Ewing sarcoma, we retrieved publicly available 
microarray gene expression data comprising genetically 
confirmed EWSR1-ETS-translocated Ewing sarcomas 
[21], 20 additional tumor entities of potential differential 
diagnostic relevance [5], and 71 normal tissue types. The 
set of morphological mimics also comprised CIC-DUX4-, 
BCOR-CCNB3-, and EWSR1-NFATc2-translocated 
sarcomas, which proved to be distinct entities as 
determined by unsupervised principal component analysis 
(PCA) (Supplementary Figure 1).
We then proceeded to perform comparative 
expression analysis on the entire dataset: Based on these 
microarray expression data the median expression of every 
gene represented on the Affymetrix HG-U133Plus2.0 
microarray was determined. Next, we calculated the 
expression ratio (ER) for every gene based on its median 
expression in pairwise comparisons of Ewing sarcoma 
and the remaining tumor entities. Only genes, which were 
strongly overexpressed in Ewing sarcoma compared to all 
other tumor entities defined by a minimal log2-transformed 
ER of > 2, were considered as diagnostically relevant. Of 
the 19,702 genes represented on the microarray platform, 
51 had an ER of > 2 across all tested tumor entities. In 
parallel, the level of significance of the differential 
expression of all genes in pairwise comparisons of Ewing 
sarcoma relative to all other tumor entities was calculated. 
Only 10 genes exhibited a Bonferroni-corrected P value < 
0.05 (Figure 1A, 1B). Next, both gene lists were crossed, 
which showed that only 3 genes, termed ATP1A1 (ATPase 
Na+/K+ transporting subunit alpha1), BCL11B (B-cell 
CLL/lymphoma 11B), and GLG1 (Golgi glycoprotein 1) 
were both strongly and highly significantly overexpressed 
in Ewing sarcoma compared to all other tumor entities 
(Figure 1B).
Then, the expression profiles of these three 
candidate biomarkers were compared to the conventional 
Ewing sarcoma by immunohistochemistry. These markers may significantly reduce the 
number of misdiagnosed patients, and thus improve patient care.
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Ewing sarcoma marker CD99 across all tumor entities. 
While CD99 showed broad expression in many different 
tumor entities, ATP1A1, BCL11B, and GLG1 were only 
expressed at low levels in every tumor entity relative to 
Ewing sarcoma, indicating a higher specificity for this 
disease than CD99 (Figure 1C). 
Because commixture of tumor tissue with normal 
cells, which could express the three markers, could 
complicate immunohistochemical evaluation, we explored 
the expression levels of ATP1A1, BCL11B, and GLG1 and 
that of CD99 in Ewing sarcoma samples relative to 71 
normal tissue types comprising 998 samples. As displayed 
in Supplementary Figure 2, ATP1A1, BCL11B, and GLG1 
were only lowly expressed in some normal tissue types, 
while CD99 was rather broadly expressed across many 
normal tissue types. In fact, our three markers, except for 
BCL11B in thymus, were statistically significantly higher 
(P < 0.05) expressed in Ewing sarcoma as compared to 
any tested normal tissue type.
EWSR1-FLI1 induces ATP1A1, BCL11B, 
and GLG1 expression by binding to GGAA-
microsatellites found in super-enhancers
The specific expression of the three candidate 
biomarkers in primary Ewing sarcoma suggests a possible 
regulatory relationship between them and EWSR1-FLI1. 
In fact, ATP1A1 and GLG1 were previously shown to 
be upregulated after ectopic expression of EWSR1-FLI1 
in the rhabdomyosarcoma cell line RD [22]. Moreover, 
BCL11B was shown to be upregulated by EWSR1-FLI1 
in Ewing sarcoma cell lines [23].
To further explore this regulatory relationship, 
available gene expression data were assessed, which 
showed that the ectopic EWSR1-FLI1 expression in 
embryonic stem cells was sufficient to significantly induce 
the expression of ATP1A1, BCL11B, and GLG1 (Figure 
2A). Conversely, the shRNA-mediated knockdown of 
EWSR1-FLI1 in six different Ewing sarcoma cell lines 
significantly decreased their expression levels (Figure 2B). 
Such consistent EWSR1-FLI1-dependent regulation was 
not observed for CD99 (Figure 2A, 2B).
These data in cell lines suggested that ATP1A1, 
BCL11B, and GLG1 may be direct EWSR1-FLI1 target 
genes. Testing this hypothesis involved analyzing 
available ChIP-Seq and DNase-Seq data generated 
in Ewing sarcoma cell lines, which showed strong 
EWSR1-FLI1-binding to GGAA-microsatellites close 
to these genes. Notably, these GGAA-microsatellites 
exhibit characteristics of active EWSR1-FLI1-dependent 
enhancers (Figure 3A). In fact, EWSR1-FLI1 is known to 
convert non-functional GGAA-microsatellites into potent 
enhancers to steer a large proportion of its target genes [24-
26]. Strong EWSR1-FLI1-dependent enhancer activity of 
these GGAA-microsatellites in luciferase reporter assays 
was consistently observed (Figure 3B). In agreement 
with previous observations [27], these EWSR1-FLI1-
dependent enhancers showed the typical H3K27ac profile 
of so-called super-enhancers in the A673 and SK-N-MC 
Ewing sarcoma cell lines (Figure 3C, Supplementary 
Tables 1 & 2). Super-enhancers are often found near 
genes that have cell type-specific functions and contribute 
to cell identity [28, 29]. In addition to these findings in 
vitro, gene-set enrichment analyses of either ATP1A1-, 
BCL11B-, or GLG1-correlated genes within 166 primary 
Ewing sarcoma tumors revealed that the most significantly 
(min. NES = 3.08, P < 0.001, q < 0.001) associated gene 
expression signature among the 3,687 tested was for each 
candidate marker ‘ZHANG_TARGETS_OF_EWSR1-
FLI1_FUSION’ [22] (Supplementary Table 3). Consistent 
with the previous finding that EWSR1-FLI1 and EWSR1-
Table 1: Composition of the TMA
Entity n
Ewing sarcoma 47
Alveolar Soft Part Sarcoma 3
Ewing-like sarcoma 17
Ganglioneuroblastoma 7
Leiomyosarcoma 5
Liposarcoma 19
Malignant Fibrous Histiocytoma 3
Nephroblastoma 21
Neuroblastoma 16
Osteosarcoma 15
Rhabdomyosarcoma 11
Synovial sarcoma 10
n total: 174
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Figure 1: ATP1A1, BCL11B, and GLG1 are strongly overexpressed in Ewing sarcoma compared to tumor entities of 
differential diagnostic relevance. A. Volcano plots of pairwise comparison of gene expression in Ewing sarcoma (EWS) and indicated 
tumor entities. Diffuse large B-cell lymphoma (DLBCL); mucosa-associated lymphoid tissue (MALT) lymphoma; malignant peripheral 
nerve sheath tumor (MPNST); alveolar rhabdomyosarcoma (ARMS); and embryonal rhabdomyosarcoma (ERMS). Genes represented in 
green color had an expression ratio > 2 (log2) and a P value < 0.05 (Bonferroni-corrected). B. Size-proportional Venn diagram showing the 
overlap of genes highly and significantly (minimal log2 expression ratio > 2; P value < 0.05, Bonferroni corrected) overexpressed in Ewing 
sarcoma relative to all other tumor entities given in A and C. C. Scatter dot plot depicting gene expression levels of ATP1A1, BCL11B, 
GLG1, and CD99 as determined by Affymetrix HG-U133Plus2.0 microarrays in primary tumors of 21 different entities. Ewing sarcoma is 
highlighted in green, Ewing-like sarcomas (CIC-DUX4 or BCOR-CCNB3 translocation positive) are highlighted in orange. Horizontal bars 
represent median expression levels. The number of analyzed samples is given in parentheses.
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ERG bind to highly similar DNA-motifs [30], all three 
genes are similarly highly expressed in Ewing sarcoma 
cell lines regardless of the specific EWSR1-ETS status 
(Supplementary Figure 3). Collectively, these data 
strongly suggest that ATP1A1, BCL11B, and GLG1 are 
direct EWSR1-ETS target genes.
ATP1A1 and GLG1 may have prognostic relevance 
in Ewing sarcoma
To explore the potential of ATP1A1, BCL11B, 
GLG1, and CD99 as prognostic biomarkers, we analyzed 
the association of their expression levels with outcome in a 
Figure 2: EWSR1-FLI1 is sufficient to induce ATP1A1, BCL11B, and GLG1 expression. A. Analysis of gene expression 
levels of ATP1A1, BCL11B, GLG1, and CD99 by Affymetrix HG-U133Plus2.0 microarrays in human embryonic stem cells after ectopic 
expression of EWSR1-FLI1 (GSE64686). Bars represent the medians. Two-tailed student’s t test. B. Analysis of gene expression levels of 
ATP1A1, BCL11B, GLG1, and CD99 by Affymetrix HG-U133A microarrays 96 h after short hairpin RNA-mediated knockdown (kd)  of 
EWSR1-FLI1 in six different Ewing sarcoma cell lines (GSE14543 and GSE27524). Data are represented as before-after plots in which 
each dot represents a cell line. Two-tailed student’s t test.
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large cohort of Ewing sarcoma patients (n = 166). Whereas 
higher ATP1A1 and GLG1 expression levels showed a 
significant correlation with better patient outcome (P = 
0.006 and P = 0.0028, respectively), BCL11B and CD99 
Figure 3: EWSR1-FLI1 binds to GGAA-microsatellites with enhancer activity located close to or within the ATP1A1, 
BCL11B, or GLG1 gene. A. Published DNase-Seq and ChIP-Seq data generated in Ewing sarcoma cell lines were displayed in the 
UCSC genome browser. shGFP, control; shEF1, shEWSR1-FLI1; GGAA-mSat, GGAA-microsatellite. B. Luciferase reporter assays in 
A673/TR/shEF1 cells containing a doxycycline (Dox)-inducible shRNA against EWSR1-FLI1 confirmed the EWSR1-FLI1-dependent 
enhancer activity of cloned GGAA-microsatellites (1 kb fragments). EWSR1-FLI1 knockdown was confirmed by qRT-PCR 72 h after 
shRNA induction. Data are presented as mean and SEM of n = 3 independent experiments. Two-tailed student’s t-test. * P < 0.05; ** 
P < 0.01; *** P < 0.001. C. Genome-wide analysis of published H3K27ac profiles of A673 and SK-N-MC Ewing sarcoma cell lines 
(GSE61944) identified super-enhancers proximal to ATP1A1, BCL11B, GLG1, and CD99. Enhancers are ranked by their H3K27ac density.
Oncotarget1593www.impactjournals.com/oncotarget
expression levels did not (Supplementary Figure 4).
High expression of BCL11B and/or GLG1 is 
sufficient to robustly diagnose Ewing sarcoma by 
IHC
To confirm the overexpression of ATP1A1, BCL11B, 
and GLG1 on the protein level, a comprehensive TMA 
including many solid tumor entities closely resembling 
Ewing sarcoma and other sarcoma entities was generated 
(Table 1). Immunohistochemical staining of the TMAs 
was carried out with anti-ATP1A1, anti-BCL11B, anti-
GLG1, and anti-CD99 antibodies, and immunoreactivity 
scores (IRS) were determined in analogy to the Remmele 
and Stegner [31] scoring system (IRS range from 0 to 
12; Figure 4A, 4b). As displayed in Figure 4B, CD99 
expression was not very specific for Ewing sarcoma 
Figure 4: High expression of BCL11B and/or GLG1 is sufficient to robustly diagnose Ewing sarcoma by IHC. A. 
Representative IHC images for the indicated marker. ATP1A1 is expressed in the cytoplasm, BCL11B in the nucleus, GLG1 at the 
perinuclear Golgi apparatus, and CD99 at the membrane. Scale bars = 100 µm. For ATP1A1, BCL11B, and GLG1 a red and for CD99 a 
brown chromogen was used. B. Scatter dot plots of the individual IRS for the indicated marker. The number of analyzed samples is given 
in parentheses. Bars represent mean IRS values, whiskers indicate the 95%-CI. Green dashed lines indicate the cut-offs to define sensitivity 
and specificity for detecting Ewing sarcoma as given in the table below. ASPS: alveolar soft part sarcoma. Ewing samples are highlighted 
in green color. C. Proposed work-flow for establishing robust diagnosis of Ewing sarcoma.
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compared to other sarcoma entities as well as Ewing-like 
sarcomas. However, CD99 reached 100% sensitivity for 
Ewing sarcoma in this TMA when applying a cut-off of 
IRS > 2. Compared to CD99, the three candidate markers 
were all less sensitive at any given cut-off, but much 
more specific (specificity 90 - 97%) when being highly 
expressed (defined as IRS > 9) (Supplementary Table 4).
Automated cut-off-finding and combination-testing 
algorithms were then applied to the samples and set of 
candidate markers to identify a minimal set of markers and 
optimal cut-offs for robustly diagnosing Ewing sarcoma 
by IHC. These analyses indicated that while CD99 is a 
very valuable marker for screening for Ewing sarcoma, 
it needs auxiliary markers to establish a robust diagnosis. 
Further analyses indicated that while ATP1A1 exhibited 
high specificity (90%), it had no additional value for 
establishing Ewing sarcoma diagnosis if it was combined 
with BCL11B and GLG1. In fact, detecting high BCL11B 
and/or GLG1 expression in CD99-high tumors reached a 
specificity for Ewing sarcoma of at least 96%, and of 99% 
if both markers were highly expressed (defined as IRS 
> 9). Strikingly, strong combined immunoreactivity for 
BCL11B and GLG1 was not observed in any of the tested 
Ewing-like sarcomas, while CD99 immunoreactivity was 
found in 15 of 17 cases (88%). 
Thus, the following work-flow is proposed to 
establish a diagnosis of Ewing sarcoma (Figure 4C): In 
the case of clinically and/or radiologically suspected 
Ewing sarcoma, a biopsy should first be stained for CD99. 
If CD99 is positive (defined as IRS > 2), confirmatory 
molecular diagnostic procedures (such as FISH, qRT-
PCR, and/or next-generation sequencing), if available, 
are preferred. If molecular diagnostic procedures are 
unavailable or the biopsy material is not suitable, an IHC-
staining for BCL11B and GLG1 as well as subsequent 
scoring according to the Remmele and Stegner system 
should be performed. Since high expression of BCL11B 
and/or GLG1 (defined as IRS > 9) was found in 79% of 
all Ewing Sarcoma cases and associated with a specificity 
of 96%, diagnosis of Ewing sarcoma should be strongly 
considered if one or both markers are highly expressed.
Collectively, our data provide evidence that fast 
and robust diagnosis of Ewing sarcoma is enabled by 
immunohistochemical detection of the super-enhancer-
driven EWSR1-ETS targets BCL11B and GLG1.
DISCUSSION
Ewing sarcoma is genetically defined by 
pathognomonic EWSR1-ETS fusion transcripts [1]. To 
date, at least 18 types of chimeric EWSR1-FLI1 transcripts 
have been reported [6]. Alternatively, EWSR1 can be fused 
with ERG, ETV1, E1A-F (alias ETV4) or FEV in Ewing 
sarcoma [6]. Although CIC-DUX4- and BCOR-CCNB3-
translocated sarcomas were shown previously to be 
distinct from EWSR1-ETS-translocated Ewing sarcomas 
[12, 32], the situation was less clear for EWSR1-NFATc2-
translocated sarcomas. In fact, these tumors were until 
recently still considered by some authors as being simply a 
variant of Ewing sarcoma [33]. However, our PCA showed 
that EWSR1-NFATc2-translocated sarcomas are clearly 
distinct from EWSR1-ETS-translocated Ewing sarcomas, 
and confirm that EWSR1-NFATc2-translocated sarcomas 
also do not show any transcriptomic similarity with neither 
CIC-DUX4- nor BCOR-CCNB3-translocated sarcomas 
(Supplementary Figure 1).
Although several molecular diagnostic tools are 
available to identify Ewing sarcoma among morphological 
mimics by detecting these gene fusions (e.g. by FISH, 
qRT-PCR, and/or direct sequencing), there are several 
limitations: All these techniques require good-quality 
DNA or RNA, which is not available in more than 10% 
of cases [11]. In addition, FISH can sometimes yield 
non-informative results [14]. Moreover, there is a risk of 
falsely diagnosing a tumor as Ewing sarcoma based on 
FISH, because break-apart of the EWSR1 gene can also be 
observed in other sarcoma entities such as desmoplastic 
small-round-cell tumor (DSRCT), clear cell sarcoma, 
angiomatoid fibrous histiocytoma, extraskeletal myxoid 
chondrosarcoma, and a subset of myxoid liposarcoma 
[34]. Conversely, PCR-based assays can yield false 
negative results as the PCR may not cover the entire 
spectrum of different EWSR1-ETS fusions. Thus, some 
authors recommend combining FISH and qRT-PCR [11]. 
However, these sophisticated techniques are not available 
in all diagnostic facilities, especially in developing 
countries, which poses a significant obstacle to accurately 
diagnosing Ewing sarcoma.
To offer a simple, fast, and cost-effective way to 
reliably diagnose Ewing sarcoma by IHC, we combined 
in silico, in vitro, and in situ analyses, and found that 
the high expression of BCL11B and/or GLG1 is nearly 
diagnostic for this disease. It was shown that both genes 
are direct EWSR1-FLI1-targets, which are specifically 
overexpressed in Ewing sarcoma. In fact, their genetic 
loci exhibit EWSR1-FLI1-dependent super-enhancers 
that usually control the expression of tissue-defining 
genes [28]. In particular, the high expression of the 
chosen markers was highly effective in discriminating 
Ewing sarcoma from EWSR1-ETS-negative Ewing-like 
sarcomas, which expressed CD99 at high levels in 88% 
of our cases. Nevertheless, it should be noted that some 
small-round-cell sarcoma subtypes such as DSRCTs 
could not be included in our primary screen as compatible 
gene expression microarrays were not publicly available. 
However, Surdez et al. published a transcriptomic 
comparison of DSRCTs and the same Ewing sarcoma 
samples as used in the current study, which proved 
that none of our markers ranges among the top 150 
overexpressed probesets in DSRCT [35]. This finding was 
replicated in a subsequent study [25].
Previously, another EWSR1-FLI1 target gene, 
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NKX2-2, was proposed to serve in combination with 
CD99 as a useful immunohistochemical marker for Ewing 
sarcoma [36]. In our comparative microarray analyses, 
NKX2-2 did not, however, meet the stringent selection 
criteria for further validation. Similarly, another report 
showed that NKX2-2 is not fully specific for Ewing 
sarcoma [20]. 
Although most Ewing sarcoma tumors show 
only little infiltration by lymphocytes [37], the fact that 
BCL11B is expressed in normal T cells (Supplementary 
Figure 2) should be taken into account when assessing 
immunoreactivity in small-round-cell tumors. In 
indeterminate cases, a CD3 staining may be helpful 
(Supplementary Figure 5).
In agreement with similar findings on different 
markers in other cancer entities [38, 39], ATP1A1 
and GLG1 may have diagnostic as well as prognostic 
utility. However, this finding needs to be validated in an 
independent and larger cohort on the protein level.
Interestingly, all three original candidate markers 
play a role in fibroblast growth factor (FGF)-signaling. 
ATP1A1 is required for unconventional secretion of FGF 
[40], BCL11B promotes FGF-signaling by transcriptional 
suppression of a negative feedback inhibitor [23, 41], 
and GLG1 (alias cysteine-rich FGF receptor) is known to 
regulate intracellular levels of FGF [42]. Several studies 
have shown that FGF promotes EWSR1-FLI1 expression 
[43] and growth of Ewing sarcoma cells in vitro and in 
vivo [25, 41], and that FGF-inhibitors could be used as 
a targeted treatment for Ewing sarcoma patients [44]. 
Although more work needs to be done to elucidate the 
precise role of ATP1A1, BCL11B, and GLG1 in FGF-
signaling, it is tempting to speculate that they could 
serve as predictive biomarkers for the efficacy of FGF-
inhibitors.
Collectively, we propose utilizing BCL11B and 
GLG1 as novel biomarkers for the diagnosis of Ewing 
sarcoma and recommend validating their diagnostic 
value in a prospective and multi-centered setting. It will 
be essential to further develop and characterize specific 
monoclonal antibodies directed against these proteins to 
improve and standardize their diagnostic utility.
MATERIALS AND METHODS
Human samples and ethics approval
Human tissue samples were retrieved from the 
archives of the Institute of Pathology of the LMU Munich 
(Germany), the Department of Pathology, Turgut Ozal 
Medical Center, Inonu University (Turkey), the Başkent 
University Hospital (Turkey), the Gerhard-Domagk-
Institute for Pathology of the University of Münster 
(Germany), the Institute of Biomedicine of Seville (Spain), 
and the Bone Tumour Reference Centre at the Institute of 
Pathology of the University Hospital Basel (Switzerland) 
with approval of the corresponding institutional review 
boards. The LMU Munich’s ethics committee approved 
the current study (approval no. 550-16 UE).
Microarray analyses
Publicly available gene expression data generated 
with the Affymetrix HG-U133Plus2.0 DNA microarray for 
1,790 samples comprising 21 tumor entities and 71 normal 
tissue types were retrieved from several repositories. 
Accession codes are given in Supplementary Table 5. 
All Ewing sarcoma samples were genetically verified to 
contain a specific EWSR1-ETS translocation as previously 
described [21]. After rigorous quality-checks (including the 
Relative Log Expression (RLE) and Normalized Unscaled 
Standard Error (NUSE)) and careful clinical annotation 
validation, expression intensities were calculated 
simultaneously with the Robust Multi-array Average 
(RMA) algorithm (including background adjustment, 
quantile normalization, and summarization), using custom 
brainarray chip description file (CDF, ENTREZG, V19), 
which yielded one optimized probe-set per gene [45]. 
The pairwise ER of every gene was calculated based on 
its median expression levels in primary Ewing sarcoma 
tumors and any of the 20 other remaining tumor entities. 
The differential gene expression’s statistical significance 
was calculated with an unpaired, two-tailed Student’s 
t-test. The resulting P values were adjusted for multiple 
testing with the Bonferroni method. Only genes with an 
ER of > 2 between Ewing sarcoma and any other tumor 
entity and a Bonferroni-corrected P value < 0.05 across 
all tumor entities compared with Ewing sarcoma were 
considered diagnostically relevant. PCA was performed in 
R [46]. Publicly available gene expression microarray data 
for ectopic EWSR1-FLI1 expression in embryonic stem 
cells (Affymetrix HG-U133Plus2.0; GSE64686 [47]) and 
from Ewing sarcoma cell lines that were either transiently 
transfected with an shRNA directed against EWSR1-FLI1 
or a control shRNA (TC252, SK-N-MC, STA-ET-7.2, 
STA-ET-1, WE68; Affymetrix HG-U133A; GSE14543 
[48]) or stably transduced with a doxycycline-inducible 
shRNA against EWSR1-FLI1 (A673; Affymetrix HG-
U133A 2.0; GSE27524 [49]) were normalized by RMA 
using custom brainarray CDF (ENTREZG, v19).
To identify the pathways and biological processes 
associated with a given gene present in normalized gene 
expression data from primary Ewing sarcoma tumors, 
gene-set enrichment analyses (GSEAs) were performed 
on ranked lists of genes in which all genes were ranked by 
their correlation coefficient with the given reference gene 
(MSigDB, c2.all.v5.1). GSEA was carried out with 1,000 
permutations in default settings [50].
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Analysis of DNase-Seq and ChIP-Seq data, and 
genome-wide identification of super-enhancers
Publicly available data were retrieved from the 
Gene Expression Omnibus (GEO). ENCODE SK-N-
MC DNase-Seq (GSM736570) [51] were analyzed in the 
Nebula environment [52] using Model-based Analysis 
of ChIP-Seq v1.4.2 (MACS) [53] and converted to 
*.wig format for display in the UCSC Genome Browser 
[54]. Preprocessed ChIP-Seq data from Riggi et al. [55] 
(GSE61944) were converted to *.wig format with the 
UCSC’s bigWigToWig conversion tool. 
The following samples were used in this study:
ENCODE_SKNMC_hg19_DNAseHS_rep2
GSM1517546 SKNMC.shGFP96.FLI1
GSM1517555 SKNMC.shFLI196.FLI1
GSM1517547 SKNMC.shGFP96.H3K27ac
GSM1517556 SKNMC.shFLI196.H3K27ac
GSM1517569 A673.shGFP48.FLI1
GSM1517572 A673.shFLI148.FLI1
GSM1517571 A673.shGFP96.H3.k27ac
GSM1517574 A673.shFLI196.H3K27ac
ChIP-seq data of the histone modification H3K27ac 
in A673 and SK-N-MC Ewing sarcoma cell lines 
(shGFP96) from a genome-wide chromatin analysis 
(GSE61944) conducted by Riggi et al. [55] were used 
for epigenetic analysis of enhancers. The already aligned 
Sequence Read Archives (*.sra) of both cell lines and the 
corresponding whole cell extracts were downloaded from 
GEO. Before peak calling with MACS2 [53], the data 
were prepared with SAMtools [56]. ChIP peak annotation 
was done with HOMER [57]. Super-enhancers were 
identified with ROSE [28, 58].
Cell culture, DNA constructs, and reporter assays
A673/TR/shEF1 Ewing sarcoma cells, which 
harbor a doxycycline-inducible shRNA against EWSR1-
FLI1, were described previously [59] and kindly provided 
by J. Alonso (Madrid, Spain). Unmodified A673 cells 
were obtained from ATCC. All cells were grown at 
37°C in 5% CO
2
 in a humidified atmosphere in RPMI 
1640 medium (Biochrom) containing 10% Tetracycline-
free FCS (Biochrom), 100 U/ml penicillin, and 100 μg/
ml streptomycin (both Biochrom). Cell line purity was 
confirmed by short tandem repeat profiling (latest profiling 
15th December 2015), and cells were checked routinely 
for the absence of mycoplasma by PCR. Human GGAA-
microsatellites close to the ATP1A1, BCL11B, or GLG1 
gene were cloned from the A673 Ewing sarcoma cell line 
into the pGL3-luc vector (Promega) upstream of the SV40 
minimal promoter. -Primer sequences were as follows: 
forward 5’-CTAGCCCGGGCTCGAGAGCAA 
CACAAGGACTCAATTAC-3’ and reverse 
5’-GATCGCAGATCTCGAGCTACTATGATGCAAA 
GCTGAGTG-3’ for the ATP1A1 associated GGAA-
microsatellite;
forward 5’-CTAGCCCGGGCTCGAG 
GCCGTCTCTCTGTTCCTTAT-3’ and reverse 
5’-GATCGCAGATCTCGAGAATCTCTGCTCCT 
TCATCCC-3’ for the BCL11B associated GGAA-
microsatellite; and
forward 5’-CTAGCCCGGGCTCGAGGCTACTATAGCCAA 
ATGCAAAGAAGAA-3’ and reverse 5’-GATCGCAGATCTCGAG TGCACTGGGTTATA-
CAGAAAGAGTTC-3’ for the GLG1 associated GGAA-
microsatellite.
For the reporter assays, 3 × 105 A673/TR/shEF1 
cells per well of a six-well plate were seeded in 2.5 ml 
medium and transfected with pGL3-luc vectors and Renilla 
pGL3-Rluc (ratio, 100:1) using Lipofectamine LTX and 
Plus Reagent (Invitrogen). After 4 h transfection media 
were replaced by media with or without doxycycline (1 
μg/ml). Cells were lysed after 72 h and assayed with a 
dual luciferase assay system (Berthold). Firefly luciferase 
activity was normalized to Renilla luciferase activity.
RNA extraction, reverse transcription, and 
quantitative real-time PCR (qRT-PCR)
RNA was extracted with the Nucleospin II kit 
(Macherey-Nagel) and reverse-transcribed using the 
High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). qRT-PCRs were performed using SYBR 
green (Applied Biosystems). Oligonucleotides were 
purchased from MWG Eurofins Genomics. Reactions 
were run on a Bio-Rad CFX Connect instrument and 
analyzed using Bio-Rad CFX Manager 3.1 software. 
Primer sequences for EWSR1-FLI1 and RPLP0 were 
reported previously [25].
Construction of TMAs and IHC
A total of 174 archival formalin-fixed and paraffin-
embedded (FFPE) primary tissue samples with reviewed 
histological diagnosis were obtained from the participating 
institutions and collected at LMU Munich’s Institute of 
Pathology. Representative FFPE tumor blocks were also 
selected for TMA construction at LMU Munich’s Institute 
of Pathology. A detailed description of the TMA is given 
in Table 1.
All Ewing sarcoma FFPE samples showed 
cytogenetic evidence for a translocation of the EWSR1 
gene as determined by fluorescence in situ hybridization 
(FISH) and were reviewed by a reference pathologist. For 
this study, Ewing-like sarcomas were defined as small-
round-cell sarcomas being either positive for CIC-DUX4 
Oncotarget1597www.impactjournals.com/oncotarget
(8 cases) or BCOR-CCNB3 (2 cases) or unclassified (7 
cases) after extensive reference pathologist work-up. Each 
TMA slide contained three cores (each 1 mm in diameter) 
from every sample as well as internal controls. 
For IHC, 4 μm sections were cut, and antigen 
retrieval was performed with microwave treatment with 
750 W at pH7.5 TRIS buffer (2 x 15 min) using the 
antigen retrieval AR kit (DCS, HK057-5KE) for GLG1 or 
the Target Retrieval Solution (Dako, S1699) for BCL11B 
and ATP1A1. Blockage of endogenous peroxidase was 
performed using 7.5% aqueous H
2
O
2
 solution at room 
temperature and blocking serum from the corresponding 
kits for 20 min.
Slides were then incubated for 60 min with 
the primary antibodies anti-ATP1A1 (1:330 dilution, 
Proteintech, 14418-1-AP) [60], anti-BCL11B (1:1,000 
dilution, Abcam, ab70453) or anti-GLG1 (1:250 dilution, 
Sigma, HPA010815) [61]. Then slides were incubated with 
a secondary anti-rabbit IgG antibody (ImmPress Reagent 
Kit, Peroxidase-conjugated) followed by target detection 
using AECplus chromogen for 10 min (Dako, K3461).
For IHC of CD99, 4-μm sections were cut and 
incubated for 32 min with an anti-CD99 antibody (1:40 
dilurion, Dako, 12E7) using the Roche UltraView 
detection kit.
Evaluation of immunoreactivity and automated 
cut-off finding
Semi-quantitative evaluation of marker 
immunostaining was carried out by three independent 
observers (MCB, MD, MFO) analogous to scoring of 
hormone receptor IRS ranging from 0-12 according 
to Remmele and Stegner [31], which is routinely used 
in surgical pathology to quantify hormone receptor 
expression in mammary carcinoma.
The percentage of cells with marker expression was 
scored and classified in five grades (grade 0 = 0-19%, 
grade 1 = 20-39%, grade 2 = 40-59%, grade 3 = 60-79% 
and grade 4 = 80-100%) after examination of 10 high-
power fields (40×) of at least one section per sample. In 
addition, the intensity of marker immunoreactivity was 
determined (grade 0 = none, grade 1 = low, grade 2 = 
moderate and grade 3 = strong). The product of these two 
grades defined the final IRS. Sensitivity and specificity of 
each marker for Ewing sarcoma were calculated with an 
in-house generated VBA (Visual Basic for Applications) 
script implemented in Microsoft Excel (Microsoft). The 
script computed sensitivity and specificity for all possible 
combinations of markers and within these combinations, 
for all possible cut-offs for every marker. The best 
marker and cut-off combination was chosen based on the 
following criteria: high specificity (defined as > 95%), 
high sensitivity, and discriminability between positive 
(IRS higher than the cut-off) and negative samples.
Survival analysis
Microarray data of 166 primary Ewing sarcoma 
tumors (GSE63157 [62], GSE34620 [21], GSE12102 
[63], and GSE17618 [64]), which had well-curated 
clinical annotations available, were downloaded from 
the GEO. The data were generated on Affymetrix HG-
U133Plus2.0 or Affymetrix HuEx-1.0-st microarray 
chips and normalized separately by RMA using custom 
brainarray CDF files (v20). Batch effects were removed 
using ComBat [65, 66]. Samples were stratified into 
two groups based on their median intra-tumoral gene 
expression levels. Significance levels were calculated with 
a Mantel-Haenszel test. P values < 0.05 were considered 
statistically significant.
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